RZLT Price / Book | REZOLUTE, INC.

Rezolute, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

Rezolute, Inc. price/book ratio for the quarter ending 2026-06-30 was 4.97, a 108.11% increase year-over-year.
Rezolute, Inc. price/book ratio for the quarter ending 2026-03-31 was 2.5, a 17.44% increase year-over-year.
Rezolute, Inc. price/book ratio for the quarter ending 2025-12-31 was 1.77, a 40.73% decline year-over-year.
Rezolute, Inc. price/book ratio for the quarter ending 2025-09-30 was 5.82, a 145.66% increase year-over-year.
Rezolute, Inc. price/book ratio for fiscal 2026 was 4.97.
Rezolute, Inc. price/book ratio for fiscal 2025 was 1.77, a 40.73% decline from fiscal 2024.
Rezolute, Inc. price/book ratio for fiscal 2024 was 2.98, a 594.34% increase from fiscal 2023.
Rezolute, Inc. price/book ratio for fiscal 2023 was 0.43, a 20.51% decline from fiscal 2022.

Available history: 2013-03-31 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	4.97	$500.35M	$100.69M
2026-03-31	2.5	$291.77M	$116.83M
2025-12-31	1.77	$225.97M	$128M
2025-09-30	5.82	$856.2M	$147.17M
2025-06-30	2.39	$387.13M	$162.13M
2025-03-31	2.13	$175.57M	$82.57M
2024-12-31	2.98	$296.62M	$99.59M
2024-09-30	2.37	$268.66M	$113.44M
2024-06-30	1.89	$228.96M	$121M
2024-03-31	1.44	$102.34M	$70.86M
2023-12-31	0.43	$39.35M	$91.73M
2023-09-30	0.47	$48.61M	$103.56M
2023-06-30	0.63	$72.92M	$116.17M
2023-03-31	0.56	$70.71M	$127.32M
2022-12-31	0.54	$76.23M	$141.27M
2022-09-30	0.66	$100.91M	$153.09M
2022-06-30	0.73	$108.47M	$149.47M
2022-03-31	1.01	$52.58M	$51.91M
2021-12-31	1.19	$74.36M	$62.27M
2021-09-30	3	$64.62M	$21.56M
2021-06-30	4.57	$119.18M	$26.1M
2021-03-31	2.02	$58.97M	$29.13M
2020-12-31	2.79	$100.14M	$35.89M
2020-09-30	28.85	$126.43M	$4.38M
2020-06-30	3.7	$27.28M	$7.37M
2020-03-31	0.1	$1.03M	$10.33M
2019-12-31	0.11	$1.69M	$14.69M
2019-09-30	0.11	$2.2M	$20.62M
2019-06-30	23.78	$41.66M	$1.75M
2019-03-31	133.05	$618.66M	$4.65M
2018-12-31	-28.44	$278.4M	-$9.79M
2018-09-30	-168.85	$1.09B	-$6.44M
2018-06-30	-0.35	$1.4M	-$3.96M
2018-03-31	2,293.09	$1.22B	$532,930.00
2017-12-31	629.37	$2.39B	$3.8M
2017-09-30	344.15	$2.69B	$7.81M
2017-06-30	326.15	$2.78B	$8.53M
2017-03-31	268.62	$2.27B	$8.46M
2016-12-31	258.12	$2.05B	$7.93M
2016-09-30	309.09	$2.54B	$8.2M
2016-06-30	200.11	$1.76B	$8.77M
2016-03-31	1,283.73	$1.44B	$1.12M
2015-12-31	470.29	$1.78B	$3.78M
2015-09-30	261.12	$1.76B	$6.76M
2015-06-30	262.1	$2.37B	$9.05M
2015-03-31	272.85	$2.65B	$9.7M
2014-12-31	175.92	$1.38B	$7.82M
2014-09-30	299.45	$1.5B	$5.02M
2014-06-30	385.46	$2.47B	$6.41M
2014-03-31	746.36	$2.54B	$3.41M
2013-12-31	-1,446.52	$6.36B	-$4.4M
2013-09-30	-1,494.88	$7.2B	-$4.82M
2013-06-30	-368.07	$1.53B	-$4.16M
2013-03-31	-4,732.12	$16.8B	-$3.55M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	4.97	$500.35M	$100.69M
2025-12-31	1.77	$225.97M	$128M
2024-12-31	2.98	$296.62M	$99.59M
2023-12-31	0.43	$39.35M	$91.73M
2022-12-31	0.54	$76.23M	$141.27M
2021-12-31	1.19	$74.36M	$62.27M
2020-12-31	2.79	$100.14M	$35.89M
2019-12-31	0.11	$1.69M	$14.69M
2018-12-31	-28.44	$278.4M	-$9.79M
2017-12-31	629.37	$2.39B	$3.8M
2016-12-31	258.12	$2.05B	$7.93M
2015-12-31	470.29	$1.78B	$3.78M
2014-12-31	175.92	$1.38B	$7.82M
2013-12-31	-1,446.52	$6.36B	-$4.4M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Turn Therapeutics Inc. (TTRX)	United States	$0.397B	-25.68
GALECTIN THERAPEUTICS INC (GALT)	United States	$0.399B	-11.06
Arcturus Therapeutics Holdings Inc. (ARCT)		$0.402B	-2.05
Opus Genetics, Inc. (IRD)	United States	$0.406B	-3.16
RELMADA THERAPEUTICS, INC. (RLMD)	United States	$0.406B	-11.92
Vogenx, Inc. (VOGX)	United States	$0.355B
ARS Pharmaceuticals, Inc. (SPRY)	United States	$0.414B	-3.70
Atea Pharmaceuticals, Inc. (AVIR)	United States	$0.414B	-2.26
ENANTA PHARMACEUTICALS INC (ENTA)	United States	$0.349B	-6.72
Emergent BioSolutions Inc. (EBS)	United States	$0.347B	-2.43